Introduction
In recent years the number of cardiac implantable electronic device (CIED) complications has increased as a result of an increasing number of CIED implantations. In parallel with this development a rise in lead malfunctions and recalls accompanying the complex CIED procedures in high risk patients has resulted in increased transvenous lead extractions (TLE) [1] [2] [3] [4] [5] . In the last 15 years numerous reports of single and multi-centre TLE experiences have formed the basis of guidelines for the practice of TLE 2, 3 although the safety and efficacy of the current practice of 'real-world' lead extraction is unclear. In a European survey conducted by EHRA in 2012 the success rates and complications of TLE techniques showed that TLE was still underdeveloped across European countries with divergent practices between centres. 4, 5 The European Lead Extraction ConTRolled
Registry (ELECTRa), conducted by the European Heart Rhythm Association (EHRA), was designed as a large multicentre prospective registry of consecutive TLE procedures with the aim of identifying the safety and efficacy of the current clinical practice of TLE. In addition, individual European centres were categorized as low (LoV < 30 TLE procedures/year) and high (HiV > _ 30 TLE procedures/year) volume centres with the aim of identifying the safety and efficacy according to centre volume. 6 
Methods

Study design, patients, and data management
The executive committee composed of two co-chairs (MGB, CK) in addition to regional co-ordinators that were responsible for specific European regions. The executive committee in co-operation with the EURObservational Research Program (EORP) provided the study design, protocol, and the scientific leadership of the registry under the responsibility of the EHRA Scientific Initiatives Committee (SIC). All EHRA affiliated centres in Europe performing TLE (irrespective of volume) were identified and invited by EHRA and the regional co-ordinators to participate. Participating centres were required to recruit all consecutive patients with an indication for TLE (excluding those patients primarily requiring surgical extraction) in their institution. All subjects provided written informed consent prior to the extraction procedure. No specific protocol or recommendations regarding technique were made for the TLE procedure. Importantly operators were asked to define their intention to treat prior to the procedure, i.e. the number of leads targeted to be removed, so that failure to achieve the pre-specified intention could be identified. This was important in cases of non-infective indications where removal of all leads may not have been necessary. Data were prospectively collected using a secure web-based database system. Source data and database quality control was performed by dedicated data monitors to ensure the integrity of the data and to ensure that all consecutive patients were included. A detailed description of the study design and of the electronic case report form (e-CRF) has been previously described. 6 
Definitions
Definitions published in the guidance documents by HRS (2009) 7 and by EHRA (2012) 3 were used to define procedural approaches, techniques, and outcomes. Sheaths were classified as mechanical non-powered (polypropylene or similar plastic material) or powered (laser, radio-frequency electrosurgical or controlled-rotational with threaded tip devices). TLE safety and efficacy were calculated by evaluating the rate of procedure related complications (major and minor) and success/failures (radiological and clinical). Major complications were defined as those related to the procedure that were life threatening or resulted in death, or any unexpected event that caused persistent or significant disability, or any event that required significant surgical intervention to prevent any of outcomes listed above. The complication's relationship with the procedure was defined by the physician as being procedure related or not and if so as directly or indirectly related to the performance of the procedure. 8, 9 Intra-procedural complications were defined as any event related to the performance of the procedure that occurred or became evident from the time the patient entered the operating room or catheterization laboratory until the time the patient left the operating room (including complications related to patient preparation, anaesthesia, and incision opening or closing). Post-procedural complications were defined as any other such event occurring after the procedure until patient discharge. All cause in-hospital major complications including deaths were all major complications including deaths irrespective of its classified relation to the procedure. Radiological failure (considered for each lead) was defined when more than a 4 cm length of a lead was abandoned after a removal attempt, partial success when less than a 4 cm of a lead remained in the patient body and complete success when the lead was completely removed. Clinical failure (considered for each patient) was defined when, as either a procedure related major complication or a failure to achieve the clinical outcome for which the TLE was scheduled, occurred. High volume (HiV) and low volume (LoV) centres were defined as > _ 30 and < 30 TLE procedures/year, respectively, on the basis of their volume of activity according to EHRA consensus document. 3 
Study endpoints
The primary endpoint was the safety of TLE as defined by procedurerelated major complications and deaths observed during the hospitalization. Secondary endpoints included radiological and clinical success rates of TLE and all cause in-hospital major complications as well as baseline patient and lead characteristics, indications for TLE, techniques, and tools used. Predictors of success and major complications were also evaluated. Success rates and complications were compared between HiV and LoV centres according to previous definitions.
Statistical analysis
Univariate analysis was applied to both continuous and categorical variables. 
Primary endpoint
The primary endpoint of procedure-related major complications, including death occurred in 58 (1.7% [95% CI 1.3-2.1%]) patients ( Table 2) . These were intra-procedural ( Transvenous Lead Extraction in Europe electromechanical dissociation and the other patient who had peripheral vessel lesion was diagnosed late with bleeding after a femoral approach. Of the 47 patients who underwent therapeutic interventions for the major cardiovascular complications 37 (78.7%) patients survived (26 IP, 11 PP). Mortality related to cardiovascular complications occurred in 12 patients (0.3%). The other procedure-related major complications, observed in 13 patients, were heart failure, sepsis, multi-organ failure, arrhythmias, acute superior vena cava syndrome, acute abdominal occlusion, and disseminated intravascular coagulation occurring in one patient each, and cerebrovascular accident, respiratory arrest, and anaesthesia related complications occurring in two patients each, all resulting in 5 deaths, in the PP period.
Minor complications, observed in 5% [95% CI 4.3-5 .7%] of patients, are reported in Table 2 .
Specific details of all procedure-related deaths are reported in Table 3 .
Secondary endpoints
All cause in-hospital major complications were observed in 95 patients ( 3% ], details of which together with the procedural characteristics are reported in Table 2 .
Outcomes in HiV and LoV centres
Differences between high volume and low volume centres regarding patients characteristics, leads characteristics, TLE indications, outcomes, and procedural characteristics are reported in the Supplementary material online, Tables S1 and S2. Patients in high and low volume centres did not differ in terms of age or indication for extraction. Patients in high and low volume centres had a similar dwell time of implanted leads (6.5 ± 5.4 vs. 6 .2 ± 5.3 years, P = 0.0819) and there was no difference in the number of leads extracted per patient. High volume centres were more likely than low volume centres to perform TLE in an OR compared with a catheter laboratory (57.3% vs. 27.5%, P < 0.0001). Procedures in high vs. low volume centres were associated with a shorter procedure duration and extraction time and a significantly shorter duration of hospital stay (6.0 ± 8.1 vs. 8.4 ± 10.6 days, P < 0.0001). Leads 
Mortality and complications
Procedure-related major complications, including deaths, occurred in 58 (1.7%) patients [15 patients (2.4%) in LoV centres and 43 patients (1.5%) in HiV centres, P = 0.1103]. These were IP in 37 (1.1%) patients Table 3 . Minor complications: pericardial effusion not requiring pericardiocentesis or surgical intervention 0.8%, haemothorax not requiring a chest tube 0.1%, haematoma at the surgical site requiring drainage 1.1%, arm swelling or thrombosis of implant veins resulting in medical intervention 0.8%, vascular repair near the implant site or venous entry site 0.1%, migrated lead fragment without sequelae 0.1%, blood transfusion related to blood loss during surgery 0.8%, pneumothorax requiring a chest tube 0.3%, pulmonary embolism not requiring surgical intervention 0.5%, femoral vein thrombosis 0.1%, tricuspid regurgitation 0.1%, pocket haematoma not requiring drainage 0.1%, arrhythmias 0.1%, transient renal failure 0.1%, and others 0.2%. c Other: renal failure 1pt (0.03%), major bleeding 1pt (0.03%), and colon cancer 1pt (0.03%). Figure 2B) . Predictors of increased all cause mortality during hospitalization were: extraction in a low volume centre (OR 2.02, 95% CI 1.07-3.81, P = 0.0299), age >68 years (OR 2.42, 95% CI 1.26-4.66, P = 0.0079), NYHA Class III/IV (OR 4.08, 95% CI 2.24-7.43, P < 0.0001) and systemic infection (OR 4.93, 95% CI 2.72-8.93, P < 0.0001) ( Figure 2C ).
Discussion
The ELECTRa registry is the first large prospective controlled registry on consecutive TLE procedures conducted by an independent scientific society (EHRA/ESC) in Europe. With a total of 73 out of 116 invited centres from 6 major European macro-areas and 19 different countries participating on a voluntary basis in the registry, it represents to date the largest reflection of the current practice of TLE. The majority of patients were recruited from three countries (Italy, Poland, and France) (Figure 1 ) and patient and lead characteristics were similar to those reported in other contemporary TLE publications. 2 Manual traction, without specific tools for extraction, was only effective in 27.3% [95% CI 26. 2-28.4 ] of leads and the use of locking stylets, dilators, powered and non-powered sheaths were often required. The incidence of major complications including death was low and in line with complication rates observed in previously reported experiences. Two-thirds of procedure-related major complications and deaths occurred during the procedure and one-third in the postoperative period. Procedure related major complications were frequently due to cardiac avulsion and vascular damage and major nonprocedural related complications to heart failure and sepsis. Our findings suggest that TLE is a safe and effective procedure from a multicentre perspective with its inherent heterogeneous TLE competences, given the limitations with a non-compulsory registry. The observation that complications often occur after the procedure supports the importance of an appropriate multi-disciplinary patient and lead management approach.
In the multivariate analyses independent predictors of procedural related complications and failure were explored. Apart from previously identified well known predictors of complications 8, 10 we identified that clinical failure was more common for leads with a prolonged dwell time, for extraction of multiple leads, the requirement for powered sheaths, a femoral approach and for procedures performed at low volume centres. These factors were also predictors of procedure related complications (Figure 2) .
Procedural risk appeared to be dependent on lead-and procedural related predictors. Lead related predictors are not modifiable but, once identified, may be used to stratify the procedural risk. Accordingly, TLE of multiple leads with a long implantation time should be considered carefully. Certain procedural factors impacted on the final outcome and were independent predictors not only of failure but also of major complications. Powered sheaths and trans-femoral routes were associated with a higher rate of complications especially if used in the used in the LoV centres. Such technical issues are difficult to identify and are beyond the scope of the present study, which was not designed to demonstrate the superiority of specific TLE techniques (mechanical vs. powered) and approaches (superior venous entry vs. trans-femoral). This novel finding that femoral access was less safe in comparison to other approaches still warrants some precautions regarding choice of environmental facility, operator experience and risk profile of the patient in order to minimize the risk for complications. Defining the optimal TLE procedure with the best risk-benefit balance is likely dependent on patient selection and centre/operator experience and related factors, which however mandates further analysis and optimally adequately designed randomized trials.
A suitable centre volume and operator experience would appear to impact the safety and success rate however the current study was not designed to define this and the predefined division of HiV and LoV centres used an arbitrary cut-off of 30 cases per centre per year which was based on previous consensus statements regarding centre experience and training [4] [5] [6] [7] . The Electra registry confirmed the inverse relation between major complications and procedural centre volume ( Figure 3 ) but as this was not the primary endpoint of the study we cannot clearly define the appropriate number of procedures per centre per year in order to minimize the complications related to the procedure. The observation that procedures in high vs. low volume centres were associated with shorter procedure duration and significantly shorter duration of hospital stay may also have important financial implications.
The finding that older and sicker patients had an increased all cause mortality, independent of the procedure highlights the challenge of the clinical management of these patients especially after the TLE procedure. The finding of a higher all cause in-hospital major complications and death rate in LoV vs. HiV centres (4.1 vs. 2.4%, P = 0.01 and 2.5 vs. 1.2%, P = 0.008, respectively) suggests that the outcome of TLE is not only confined to the TLE procedure per se but is dependent on multiple patient factors and co-morbidities that require an advanced and high skilled multi-disciplinary team management that may only be facilitated in HiV centres. In the event of major complications occurring after the procedure, patients may often be saved, if complications are recognized and treated promptly.
In summary the ELECTRa study findings confirm the previously described observations 4, 8 that TLE procedure is a safe and effective treatment, with an acceptable risk benefit ratio but with potential lifethreatening complications (Figure 4) . According to published data 15 and confirmed by this large registry, predictors of complications are multivariate and not only related to the patient/lead profile but also to centre experience and procedure volumes.
Study limitations
The ELECTRa findings are subject to the limitations inherent to observational studies, including the possibility of unknown confounders and bias in management strategy. To ensure data integrity source data and database quality control was performed by dedicated data monitors to ensure that all consecutive patients were included in participating centres. Operators also had to state an intention to treat with the number of leads targeted for extraction thus defining clinical success in advance of the procedure. The participation in the ELECTRa registry was based on a voluntary basis: and complication rates may therefore be underestimated since there are centres, physicians and surgeons performing lead extraction that did not participate in the Registry. Although there was participation from all of the major centres/countries performing extraction the patients recruited may not represent the practice of lead extraction in all countries. This may be the case for certain countries such as Germany which is one of the largest volume countries in Europe for lead extraction and where a high proportion of lead extraction is undertaken by non-EHRA affiliated centres who would therefore not have been invited to participate in the study. Similarly patients with an indication for TLE who 
were referred for open surgical extraction were excluded from the study.
The purpose of ELECTRa was to offer a multicentre prospective overview of TLE safety and efficacy in Europe. Predictors of outcomes were identified and discussed although the exact cause-effect relationships remain speculative. The study was not designed to compare the impact of different tools, techniques, and approaches on outcomes and further data are warranted to explore this topic.
The division of high and low volumes centres using a figure of 30 cases per centre per year was based on the median of the enrolment/ year/centre and coincide with that expressed in previous consensus statements regarding centre experience and training 3, 4 and it is possible that outcomes may be even worse in very low volume centres undertaking a very small number of procedures.
Conclusions
The ELECTRa study is the first large prospective registry on TLE conducted in Europe. The current data reflect real world practice and confirms that TLE is a safe and effective procedure that it is associated with a low incidence of life-threatening complications. Patient and device/lead characteristics as well as centre-related factors were associated with both TLE success rate and major complications, including all-cause mortality. The identification of patient and procedurerelated risk factors independently associated with major complications, all-cause mortality and clinical failure have important implications regarding decision-making and therapeutic strategies in patients who are candidates for TLE.
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